Marrit Putker, Saskia De Man, and Pirouz Daftarian from Crown Bioscience discuss T cell-directed immunotherapy on the cancer-immunity cycle, including mechanisms and targets capable of modulating and enhancing T cell activity and the application of methods and models including organoids and high content imaging.
Since the role of GPR55 in adaptive B cell response regulation has not yet been reported in the context of atherosclerosis, Guillamat-Prats et al. have investigated how GPR55 in B cells affects atherosclerosis development. In this blog post, we highlight the main findings from this study, which was published this month in Nature Cardiovascular Research.
The majority of treatments for immunodeficiencies are temporary fixes, in part due to a lack of preclinical models that can accurately predict immune responses in humans. However, a novel model recently published in Nature Methods has potential to greatly improve future immune response studies, which we review in this blog post.
Cancer immunotherapy has undoubtedly expanded the cancer treatment landscape and improved patient outlook, which can in part be attributed to the recognition of the importance of the cancer-immunity cycle as a whole. In this blog, we provide an overview of the cancer-immunity cycle and highlight some preclinical models that can facilitate cancer immunotherapy research.